Labomar

Business and Financial Review • May 12, 2022

Press Release Labomar: new Biochetasi Acidità e Digestione study

The Treviso-based company has consolidated its partnership with Alfasigma, a leading Italian pharmaceutical company, collaborating in the first in vitro study into the antiacidity effect of the supplement, now in its millionth pack produced

Istrana (TV), 12 May 2022 - Labomar S.p.A. (Ticker: LBM) is an Italian-based international nutraceutical enterprise listed on the Euronext Growth Milan market, which specialises in the development and production of dietary supplements, medical devices, foods for special medical purposes and cosmetics for third parties. At the request of Alfasigma, the company has carried out a new study into the effects of Biochetasi Acidità e Digestione, a dietary supplement that helps regulate digestive processes and counteract stomach acidity. The study, "Antacid and Prodigestive Activity of a Novel Formulation", was published in the Journal of Gastrointestinal & Digestive System.

Biochetasi Acidità e Digestione is a dietary supplement based on enzymes, artichoke, fennel, rice powder, calcium carbonate and citrates that contribute to regulating digestive processes. It is suitable for the whole family (including children over 6) and can also be taken during pregnancy and while breastfeeding. Its formulation allows it to act on stomach heaviness and feelings of abdominal bloating at every stage of digestion, promoting the normal function of the digestive system and controlling gastric acidity. Labomar develops and produces the product for Alfasigma in two formats, powder sachets and chewable tablets.

The study "Antacid and Prodigestive Activity of a Novel Formulation" was conducted by a research team comprising Elisa Gaio, Federico Benetti and Erik Tedesco of EcamRicert, Francesco Ciampanelli of Labomar and Paola Benatti and Veronica Pauletto of Alfasigma. It demonstrated, for the first time in vitro, the antacid effect of Biochetasi Acidità e Digestione, monitoring the gradual pH neutralisation through a simulation of gastric liquid. Neutralisation tests were conducted from pH 2 (equivalent to a fasting condition) and pH 3 (full stomach). The pro-digestive action of Biochetasi Acidità e Digestione integrated with protease, lipase and galactosidase was evaluated by simulating in vitro the digestion of a standard diet, composed of proteins, fats and carbohydrates, with and without normal digestive enzymes (pepsin, trypsin, lipase). The results demonstrated the multifunctional effect of Biochetasi Acidità e Digestione, which acts against acidity and supports the digestion of proteins, fats and lactose with pro-digestive action. It can therefore contribute to reducing the side effects of gastric acidity and the feeling of stomach heaviness, which are caused by slow digestion as a result of overeating or poorly balanced meals.

"This is an extraordinary result that confirms the properties of a product whose effectiveness had already been widely demonstrated and which has reached and exceeded

a million packs produced at our facilities. It is an extremely significant landmark and a source of great satisfaction for our teams" noted Walter Bertin, founder and Chairperson of Labomar. "We were determined to carry out this study despite it not being necessary for a dietary supplement, and it has delivered results that will be of great use in the future. It is particularly important considering that 40% of the population suffer from digestive problems and that this figure is on the increase as a result of the pandemic1 . This study also strengthens our partnership with Alfasigma, with whom we have a long-standing and mutually beneficial relationship".

Marco Torriglia, Marketing Director of Alfasigma's Consumer Healthcare Division, commented: "We are extremely satisfied with the results we have obtained. This is further confirmation of the importance of scientific research in developing new products that are effective and high quality. These are features that distinguish not only Biochetasi Acidità e Digestione, but the entire Biochetasi product line, one of the foremost brands in the Italian market for gastric disorders".

About Alfasigma

Alfasigma is one of the leading Italian pharmaceutical companies, with a presence in over 90 countries, a workforce of around 3,000 people, R&D laboratories and 5 production plants. In Italy, Alfasigma is a leader in the prescription products market where, in addition to its strong focus on the Gastro-Intestinal segment, it also operates in a number of primary care therapeutic areas. It manufactures and sells self-medication products, nutraceuticals and dietary supplements. For more information, please visit www.alfasigma.com

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020. The 2021 figure includes, in addition to the revenues of the parent company and the Canadian Entreprises ImportFab Inc., also those for H2 of the Welcare Group and, for December alone, of Labiotre Srl. Labomar SpA's revenues in 2021 were approx. Euro 53.8 million, increasing nearly 4 percentage points on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an ecommerce platform on the Chinese market. Labomar then acquired full control of Labiotre Srl, a Tuscan

¹ Source: Assosalute (2021)

enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For further information: Labomar Press Office Thanai Bernardini - +39.335.7245418 - me@thanai.it Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Investor Relations Labomar Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com Mara Di Giorgio - +39 335 7737417 - mara@twin.services

Euronext Growth Advisor Banca Mediolanum - +39 02 9049 2525 - ecm@mediolanum.it